KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Current Assets (2016 - 2025)

Eli Lilly (LLY) has disclosed Current Assets for 17 consecutive years, with $55.6 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 69.91% year-over-year to $55.6 billion, compared with a TTM value of $55.6 billion through Dec 2025, up 69.91%, and an annual FY2025 reading of $55.6 billion, up 69.91% over the prior year.
  • Current Assets was $55.6 billion for Q4 2025 at Eli Lilly, down from $62.1 billion in the prior quarter.
  • Across five years, Current Assets topped out at $62.1 billion in Q3 2025 and bottomed at $16.6 billion in Q1 2021.
  • Average Current Assets over 5 years is $28.0 billion, with a median of $22.2 billion recorded in 2023.
  • The sharpest move saw Current Assets dropped 2.26% in 2022, then surged 97.58% in 2025.
  • Year by year, Current Assets stood at $18.5 billion in 2021, then fell by 2.26% to $18.0 billion in 2022, then soared by 42.65% to $25.7 billion in 2023, then increased by 27.26% to $32.7 billion in 2024, then surged by 69.91% to $55.6 billion in 2025.
  • Business Quant data shows Current Assets for LLY at $55.6 billion in Q4 2025, $62.1 billion in Q3 2025, and $49.9 billion in Q2 2025.